10-Q/A: Solsence Inc. Restates Financials, Reports Q1 Loss

Solsence, Inc. has amended its Q1 2026 report to restate financial statements due to inventory accounting errors, revealing a net loss and material weaknesses in internal controls.

Summary

• Solsence, Inc. has filed an amendment (10-Q/A) to its quarterly report for the period ended March 31, 2026, to restate its previously issued financial statements.
• The restatement was necessary due to errors identified in historical accounting for labor and overhead included in inventories, leading to overstated inventories and misstated cost of revenue.
• As a result of the restatement, inventories were reduced by approximately $3.8 million as of March 31, 2026, and accumulated deficit increased.
• For the three months ended March 31, 2026, the company reported a net loss of $936,000, compared to a net income of $231,000 in the same period of 2025.
• Total revenue for the first quarter of 2026 decreased to $12,957,000 from $14,625,000 in the first quarter of 2025.
• The company identified material weaknesses in its internal controls over financial reporting, specifically in inventory costing and oversight/review of financial reporting and restatement activities.
• Management has re-evaluated and concluded that internal controls and disclosure controls and procedures were not effective as of March 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant restatement of financial results, material weaknesses in internal controls, and a decline in revenue and net income. The company is facing operational challenges and increased expenses.

Positives

• Despite the net loss, cash provided by operating activities for the three months ended March 31, 2026, was $1,517,000, an improvement from a negative $7,221,000 in the same period of 2025.
• The company has a clear remediation plan in place to address the identified material weaknesses in internal controls.
• Sales in the personal care ingredients category increased in Q1 2026 compared to Q1 2025.

Negatives

• The company reported a net loss of $936,000 for the three months ended March 31, 2026, a significant decline from a net income of $231,000 in the prior year period.
• Total revenue decreased by approximately 11.5% to $12,957,000 in Q1 2026 from $14,625,000 in Q1 2025.
• Inventories, net were restated downwards by $3.8 million as of March 31, 2026, and $3.6 million as of December 31, 2025.
• Gross profit decreased to $3,167,000 in Q1 2026 from $3,533,000 in Q1 2025.
• Selling, general and administrative expenses increased significantly to $2,799,000 in Q1 2026 from $2,108,000 in Q1 2025.
• Material weaknesses in internal controls over financial reporting were identified, indicating a risk of future misstatements.
• The company's reliance on a few key customers (67% of revenue in Q1 2026) poses a significant risk.

Risks

• The company's dependence on a limited number of key customers (67% of revenue in Q1 2026) makes it vulnerable to order cancellations or changes in customer demand.
• The identified material weaknesses in inventory costing and financial reporting oversight could lead to future material misstatements in financial statements.
• Inflationary pressures on supplier prices and wages could materially affect operations and financial position in 2026 and beyond, with potential inability to pass on all cost increases to customers.
• Potential inability to obtain working capital when needed on acceptable terms or at all.
• The terms of supply agreements with BASF could trigger a requirement to sell production equipment if performance requirements are not met.
• Uncertain demand for and acceptance of Solsence products and advanced materials.
• Potential for new governmental regulations, especially concerning nanomaterials, could be costly to comply with.

Future Outlook

The company expects that as product revenue volume increases, fixed manufacturing costs will be more efficiently absorbed, leading to increased margins. Capital spending for 2026 is projected between $0.5 million and $1.5 million, funded by operations, existing credit lines, and potential new debt financing. However, future capital requirements depend on customer acceptance, R&D progress, manufacturing expansion, and market conditions.

Management Comments

• Management identified material weaknesses in inventory costing and in oversight and review of financial reporting and restatement activities.
• Management concluded that internal controls and disclosure controls and procedures were not effective as of March 31, 2026.
• The company is implementing remediation measures for inventory costing and financial reporting oversight.
• Management believes inflation has not had a material effect on operations or financial position for 2025, but expects it may have a material effect in 2026 and beyond.

Industry Context

StockSavvy.ai notes that the restatement and identification of material weaknesses in internal controls are significant concerns for investors. The decline in revenue and shift to a net loss, coupled with increased SG&A expenses, suggest operational challenges within the beauty and life sciences markets Solsence operates in. The company's reliance on a few key customers also highlights a concentration risk.

Comparison to Industry Standards

• The restatement of financial statements due to inventory costing errors is a serious issue that deviates from standard accounting practices and erodes investor confidence.
• The identification of material weaknesses in internal controls is a red flag, as robust internal controls are a fundamental expectation for publicly traded companies.
• A decline in revenue and a shift to net losses, while not uncommon in certain industries, are concerning when combined with control deficiencies.
• Competitors in the advanced materials and personal care ingredients sectors typically aim for consistent revenue growth and profitability, with strong internal control frameworks.

Related Party Transactions

• The company has outstanding lines of credit and debt with Beachcorp, LLC and Strandler, LLC, which are affiliates of Bradford T. Whitmore, a majority shareholder.
• As of March 31, 2026, outstanding balances with Beachcorp, LLC were $12,547,000 and with Strandler, LLC were $1,000,000.
• Related party interest expense was $263,000 for the three months ended March 31, 2026, and $176,000 for the same period in 2025.

Stakeholder Impact

• Shareholders are negatively impacted by the restatement of financial results, the reported net loss, and the identification of material weaknesses in internal controls, which can erode confidence and potentially affect stock value.
• Creditors may be concerned about the company's financial performance and control deficiencies, potentially impacting future lending terms.
• Suppliers may face uncertainty regarding the company's financial stability and ability to meet payment obligations, especially given the reliance on a few key customers.

Next Steps

• Implement remediation measures for inventory costing methodologies and formalize policies.
• Evaluate and refine labor and manufacturing overhead cost pools, allocation practices, and assumptions.
• Strengthen documentation supporting burden rates, inventory valuation, and costing activities.
• Establish periodic reassessment requirements and comparisons of actual manufacturing costs with capitalized amounts.
• Enhance management review controls over inventory accounting and valuation.
• Strengthen technical cost-accounting and U.S. GAAP expertise through training, additional resources, and/or external specialists.
• Increase oversight by personnel with appropriate accounting and cost-accounting expertise.
• Enhance executive management oversight of significant accounting matters and review of third-party specialists.

Key Dates

Recommendation

The restatement of financial statements due to accounting errors, coupled with the identification of material weaknesses in internal controls, indicates significant governance and operational issues. The decline in revenue and shift to a net loss further exacerbate these concerns. The company's reliance on a few key customers adds to the risk profile. These factors suggest a high degree of uncertainty and risk, warranting a sell recommendation.

Keywords

Inventory Accounting, Financial Restatement, Internal Controls, Material Weakness, Revenue Decline, Net Loss, Cost of Revenue, Consumer Products